Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Rhapsido Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Rhapsido Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization, renewal, and quantity-limit approval for Rhapsido (remibrutinib) 25 mg tablets under the Boeing commercial formulary. It applies to providers requesting coverage for initial or continued therapy.

    Policy Summary
    PayerPrime Therapeutics
    PolicyRhapsido Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for Rhapsido and document the applicable indication, clinical criteria, specialist involvement, and safety requirements.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    25 mgRhapsido tablet strength
    60 tabletsProgram quantity limit
    30 daysQuantity-limit day supply
    12 monthsApproval duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    >6 weeks
    Required CSU symptom duration

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • ONE of the following

      • Continuation of therapy

        • The requested agent is eligible for continuation of therapy.
        • The prescriber states the patient has been treated with the requested agent within the past 90 days; treatment started with samples does not qualify.
        • The patient is at risk if therapy is changed.
      • Initial therapy

        • ONE of the following

          • Chronic spontaneous urticaria (CSU)

            • The patient has a diagnosis of chronic spontaneous urticaria (CSU).
            • The patient has had hives and itching for more than 6 weeks.
            • The prescriber has evaluated the patient to determine whether the patient is currently treated with medication known to cause or worsen urticaria (e.g., NSAIDs), in order to reduce urticaria risk.
            • ONE of the following

              • ALL of the following

                • The patient tried and had an inadequate response to the FDA-labeled maximum dose of one second-generation H1-antihistamine (e.g., cetirizine, desloratadine, fexofenadine, levocetirizine, or loratadine).
                • ONE of the following

        • ONE of the following if the patient has an FDA-labeled indication

          • The patient's age is within FDA labeling for the requested indication and agent.
          • There is support for using the requested agent for the patient's age and requested indication.
          • The patient has an indication supported in compendia for the requested agent and route of administration. Compendia support includes AHFS, DrugDex level 1, 2a, or 2b evidence, or NCCN level 1, 2a, or 2b recommended use.
        • ONE of the following if the patient has CSU

          • ALL of the following

            • The patient is currently treated with second-generation H1-antihistamine therapy (e.g., cetirizine, desloratadine, fexofenadine, levocetirizine, or loratadine).
            • The patient will continue second-generation H1-antihistamine therapy in combination with the requested agent.
          • The patient has an intolerance, hypersensitivity, or FDA-labeled contraindication to all second-generation H1-antihistamines.
        • The prescriber is a specialist in the area of the patient's diagnosis (e.g., dermatologist, allergist, or immunologist), or the prescriber has consulted with a specialist in that area.
        • ONE of the following

          • The patient will not use the requested agent in combination with another immunomodulatory agent (e.g., TNF inhibitors, JAK inhibitors, or IL-4 inhibitors).
          • ALL of the following

            • The prescribing information for the requested agent does not limit use with another immunomodulatory agent.
            • There is support for combination therapy; a copy of clinical trials, phase III studies, or guidelines is required.
        • The patient does not have any FDA-labeled contraindications to the requested agent.

    Continuation and Renewal Therapy

    Continuation and renewal therapy will be approved when ALL of the following are met:

    ALL of the following

    • The patient was previously approved for the requested agent through the plan's Prior Authorization process. Patients not previously approved require initial evaluation review.
    • The patient has had clinical benefit with the requested agent.
    • ONE of the following if the patient has chronic spontaneous urticaria (CSU)

      • The patient will continue second-generation H1-antihistamine therapy (e.g., cetirizine, desloratadine, fexofenadine, levocetirizine, or loratadine) in combination with the requested agent.
      • The patient has an intolerance, hypersensitivity, or FDA-labeled contraindication to all second-generation H1-antihistamines.

    Quantity-Limit Exception

    The quantity-limit exception will be approved when ONE of the following is met:

    ONE of the following

    • The requested quantity or dose does not exceed the program quantity limit.
    • Quantity exceeds the program limit

      • ONE of the following exception pathways

        • The requested agent does not have a maximum FDA-labeled dose for the requested indication.
        • The requested quantity or dose does not exceed the maximum FDA-labeled dose for the requested indication.
      • Applicable supporting requirement

    The requested agent must not be used concomitantly with another immunomodulatory agent, including TNF inhibitors, JAK inhibitors, or IL-4 inhibitors, unless the prescribing information for the requested agent does not limit combination use and support for combination therapy is submitted, such as clinical trials, phase III studies, or guidelines. The restriction applies to the following agents: Abrilada (adalimumab-afzb), Actemra (tocilizumab), Adalimumab, Adbry (tralokinumab-ldrm), Amjevita (adalimumab-atto), Anzupgo (delgocitinib), Arcalyst (rilonacept), Avsola (infliximab-axxq), Avtozma (tocilizumab-anoh), Benlysta (belimumab), Bimzelx (bimekizumab-bkzx), Cibinqo (abrocitinib), Cimzia (certolizumab), Cinqair (reslizumab), Cosentyx (secukinumab), Cyltezo (adalimumab-adbm), Dupixent (dupilumab), Ebglyss (lebrikizumab-lbkz), Enbrel (etanercept), Entyvio (vedolizumab), Exdensur (depemokimab-ulaa), Fasenra (benralizumab), Hadlima (adalimumab-bwwd), Hulio (adalimumab-fkjp), Humira (adalimumab), Hyrimoz (adalimumab-adaz), Icotyde (icotrokinra), Idacio (adalimumab-aacf), Ilaris (canakinumab), Ilumya (tildrakizumab-asmn), Imuldosa (ustekinumab-srlf), Inflectra (infliximab-dyyb), Infliximab, Kevzara (sarilumab), Kineret (anakinra), Leqselvi (deuruxolitinib), Litfulo (ritlecitinib), Nemluvio (nemolizumab-ilto), Nucala (mepolizumab), Olumiant (baricitinib), Omlyclo (omalizumab-igec), Omvoh (mirikizumab-mrkz), Opzelura (ruxolitinib), Orencia (abatacept), Otezla (apremilast), Otezla XR (apremilast extended-release), Otulfi (ustekinumab-aauz), Pyzchiva (ustekinumab-ttwe), Remicade (infliximab), Renflexis (infliximab-abda), Rhapsido (remibrutinib), Riabni (rituximab-arrx), Rinvoq (upadacitinib), Rituxan (rituximab), Rituxan Hycela (rituximab/hyaluronidase human), Ruxience (rituximab-pvvr), Saphnelo (anifrolumab-fnia), Selarsdi (ustekinumab-aekn), Siliq (brodalumab), Simlandi (adalimumab-ryvk), Simponi (golimumab), Simponi ARIA (golimumab), Skyrizi (risankizumab-rzaa), Sotyktu (deucravacitinib), Spevigo (spesolimab-sbzo) subcutaneous injection, Starjemza (ustekinumab-hmny), Stelara (ustekinumab), Steqeyma (ustekinumab-stba), Taltz (ixekizumab), Tezspire (tezepelumab-ekko), Tofacitinib, Tofidence (tocilizumab-bavi), Tremfya (guselkumab), Truxima (rituximab-abbs), Tyenne (tocilizumab-aazg), Tyruko (natalizumab-sztn), Tysabri (natalizumab), Ustekinumab, Velsipity (etrasimod), Wezlana (ustekinumab-auub), Xeljanz (tofacitinib), Xeljanz XR (tofacitinib extended release), Xolair (omalizumab), Yesintek (ustekinumab-kfce), Yuflyma (adalimumab-aaty), Yusimry (adalimumab-aqvh), Zeposia (ozanimod), and Zymfentra (infliximab-dyyb).

    Initial Therapy Evaluation

    Renewal Evaluation

    Renewal Evaluation

    Renewal is approved when ALL of the following are met.

    Renewal evaluation

    • The patient was previously approved for the requested agent through the plan's prior authorization process.
    • The patient has had clinical benefit with the requested agent.
    • CSU antihistamine requirement

      • The patient will continue second-generation H1-antihistamine therapy in combination with the requested agent.
      • The patient has an intolerance, hypersensitivity, or FDA-labeled contraindication to all second-generation H1-antihistamines.

    Program Parameters

    Program quantity limit
    Requested agentRhapsido (remibrutinib) 25 mg tablets
    Quantity limit60 tablets
    Day supply30 days
    CSU symptom duration
    ConditionChronic spontaneous urticaria (CSU)
    SymptomsHives and itching
    Required durationMore than 6 weeks

    Provider Requirements and Decision Risks

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required for initial approval of Rhapsido. The prescriber must document that the patient meets an eligible initial pathway: continuation of therapy requirements, an FDA-labeled indication and route, or another supported indication, including applicable age and compendia support.

    • For an FDA-labeled indication, the patient's age must be within labeling, supported for the requested indication, or supported by an allowed compendium.
    • The patient must not have any FDA-labeled contraindication to the requested agent.
    • Allowed compendia include AHFS, DrugDex level 1, 2a, or 2b evidence, and NCCN level 1, 2a, or 2b recommended use.
    Prior Authorization

    Renewal Prior Authorization

    Renewal prior authorization is required. Renewal requests are approved only when the patient was previously approved through the plan's prior authorization process, has had clinical benefit, and continues to meet the applicable CSU, specialist, concomitant-therapy, and contraindication requirements.

    Policy Background

    Rhapsido (remibrutinib) is authorized under this program for chronic spontaneous urticaria and for other FDA-labeled indications when the requested agent and route of administration are appropriate. Coverage may also be considered for a compendia-supported indication and route, including support from AHFS, DrugDex level 1, 2a, or 2b evidence, or NCCN level 1, 2a, or 2b recommended use. For chronic spontaneous urticaria, the policy addresses persistent hives and itching and requires the applicable antihistamine, specialist, safety, and concomitant-therapy criteria.

    Key Definitions

    Chronic spontaneous urticaria
    DefinitionChronic spontaneous urticaria (CSU)
    Characteristic symptomsHives and itching
    DurationLasting more than 6 weeks
    Compendia allowed
    AHFSAllowed
    DrugDexLevel 1, 2a, or 2b evidence allowed
    NCCNLevel 1, 2a, or 2b recommended use allowed

    Required Prior Therapy

    StepTreatmentDose and durationRequired outcome
    1One second-generation H1-antihistamineFDA-labeled maximum doseInadequate response
    2The same second-generation H1-antihistamineMaximally tolerated dose, titrated up to 4 times above the FDA-labeled maximum dose, for at least 2 weeksInadequate response

    Rhapsido Quantity Limit

    Rhapsido 25 mg tablets
    ProductRhapsido (remibrutinib) 25 mg tablets
    Quantity limit60 tablets
    Day supply30 days
    Policy Summary
    PayerPrime Therapeutics
    PolicyRhapsido Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for Rhapsido and document the applicable indication, clinical criteria, specialist involvement, and safety requirements.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy EvaluationRenewal EvaluationProgram ParametersProvider Requirements and Decision RisksPolicy BackgroundKey DefinitionsRequired Prior TherapyRhapsido Quantity Limit
    • The patient tried and had an inadequate response to a maximally tolerated dose of one second-generation H1-antihistamine titrated to up to 4 times above the FDA-labeled maximum dose after at least a 2-week duration of therapy.
    • There is support that the patient cannot be treated with a second-generation H1-antihistamine at a dose above the FDA-labeled maximum dose.
  1. The patient has an intolerance or hypersensitivity to one second-generation H1-antihistamine.
  2. The patient has an FDA-labeled contraindication to all second-generation H1-antihistamines.
  3. The patient has another FDA-labeled indication for the requested agent and route of administration.
  4. The prescriber is a specialist in the area of the patient's diagnosis (e.g., dermatologist, allergist, or immunologist), or the prescriber has consulted with a specialist in that area.
  5. ONE of the following

    • The patient will not use the requested agent in combination with another immunomodulatory agent (e.g., TNF inhibitors, JAK inhibitors, or IL-4 inhibitors).
    • ALL of the following

      • The prescribing information for the requested agent does not limit use with another immunomodulatory agent.
      • There is support for combination therapy; a copy of clinical trials, phase III studies, or guidelines is required.
  6. The patient does not have any FDA-labeled contraindications to the requested agent.
  7. There is support for therapy with a higher dose for the requested indication.
  8. There is support for why the requested quantity or dose cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit.
  9. The prescriber is a specialist in the area of the patient's diagnosis, or the prescriber has consulted with an appropriate specialist.
  10. Concomitant immunomodulatory therapy

    • The patient will not use the requested agent in combination with another immunomodulatory agent.
    • The patient will use the requested agent in combination with another immunomodulatory agent, the prescribing information does not limit the combination, and support for combination therapy from submitted clinical trials, phase III studies, or guidelines is provided.
  11. The patient does not have any FDA-labeled contraindication to the requested agent.
  12. High-dose H1-antihistamine trial
    TherapyOne second-generation H1-antihistamine
    Dose trialA maximally tolerated dose titrated up to 4 times above the FDA-labeled maximum dose
    Minimum durationAt least 2 weeks
    Continuation treatment window
    Therapy statusPatient has been treated with the requested agent
    Treatment windowWithin the past 90 days
    Sample initiationTreatment starting with samples is not approvable
    • Patients not previously approved require initial evaluation review.
    • Document clinical benefit with the requested agent.
    • For CSU, document continued second-generation H1-antihistamine therapy in combination with Rhapsido, or intolerance, hypersensitivity, or an FDA-labeled contraindication to all second-generation H1-antihistamines.
    • Confirm specialist prescriber or specialist consultation, applicable combination-therapy support, and absence of FDA-labeled contraindications.
    Note

    12-Month Approval Duration

    Initial and renewal approvals are issued for 12 months. A new review is required at the end of the approval period.

    • Initial approval duration: 12 months.
    • Renewal approval duration: 12 months.
    • If a quantity limit applies, also satisfy the quantity-limit criteria.
    Step Therapy

    Second-Generation H1-Antihistamine Trial

    For CSU, document an inadequate response to the FDA-labeled maximum dose of one second-generation H1-antihistamine. The record must support either titration to a maximally tolerated dose up to four times the labeled maximum for at least 2 weeks, inability to use a dose above the labeled maximum, intolerance or hypersensitivity, or an FDA-labeled contraindication to all second-generation H1-antihistamines.

    • Examples include cetirizine, desloratadine, fexofenadine, levocetirizine, and loratadine.
    • Document the drug, dose, duration, response, and reason a higher dose cannot be used when applicable.
    Documentation Required

    Diagnosis and Treatment History

    Submit documentation establishing the diagnosis and treatment history. For CSU, document hives and itching for more than 6 weeks, evaluation for medications that may cause or worsen urticaria, and the required antihistamine response, intolerance, hypersensitivity, or contraindication history.

    • Identify the requested agent, indication, route, symptom duration, prior therapies, doses, treatment duration, response, and intolerance or contraindication details.
    • Document whether the patient is currently taking a medication known to cause or worsen urticaria, such as an NSAID, and the prescriber's risk-reduction evaluation.
    • For non-CSU indications, provide the applicable FDA-label or compendia-supported diagnosis and treatment rationale.
    Documentation Required

    Specialist Involvement

    The prescriber must be a specialist in the area of the patient's diagnosis, or must document consultation with an appropriate specialist.

    • Examples include a dermatologist, allergist, or immunologist.
    • Include the specialist's name, specialty, and consultation or treatment details when the requesting prescriber is not the specialist.
    Documentation Required

    Combination-Therapy Support

    If Rhapsido will be used with another immunomodulatory agent, submit support for the combination. The prescribing information must not limit the combination, and the request must include clinical-trial, phase III study, or guideline support.

    • If combination therapy is not requested, document that Rhapsido will not be used with another immunomodulatory agent.
    • Examples of potentially relevant immunomodulators include TNF inhibitors, JAK inhibitors, and IL-4 inhibitors.
    • Submit a copy of the supporting clinical trials, phase III studies, or guidelines.
    Documentation Required

    Quantity-Limit Exception Documentation

    A quantity above the program limit requires documentation supporting the exception. The requested dose must fit one of the policy's higher-dose pathways.

    • If no maximum FDA-labeled dose exists for the indication, provide support for therapy at the higher dose.
    • If a maximum FDA-labeled dose exists, the requested quantity must not exceed it, and documentation must explain why the dose cannot be achieved with a lower quantity of a higher strength that remains within the program limit.
    • Quantity-limit approvals are issued for 12 months.
    Denial Risk

    Clinical Criteria Not Met

    The request may be denied when required clinical criteria are not met. Denial risks include an unsupported indication or age, failure to establish CSU or required treatment history, lack of specialist involvement, unsupported concomitant immunomodulatory use, or an FDA-labeled contraindication.

    • The requested indication and route must be FDA-labeled or supported under the policy's compendia criteria.
    • For CSU, hives and itching must have persisted more than 6 weeks and the required second-generation H1-antihistamine pathway must be documented.
    • The prescriber must be a relevant specialist or have consulted one.
    • The patient must not have an FDA-labeled contraindication to Rhapsido.
    Denial Risk

    Prohibited Concomitant Immunomodulatory Therapy

    Use with another immunomodulatory agent is not approvable when the prescribing information limits the combination or when supporting evidence is not submitted. Rhapsido is also listed among agents not to be used concomitantly with the prohibited therapies in the policy.

    • Document that Rhapsido will not be combined with agents in the policy's prohibited concomitant-therapy tables unless both required combination-use conditions are met.
    • The tables include biologics, TNF inhibitors, JAK inhibitors, IL-4 inhibitors, and other immunomodulators; examples include Xolair, Dupixent, Rinvoq, Xeljanz, and Rhapsido itself.
    • Unsupported or contraindicated combination use may result in denial.
    Denial Risk

    Unsupported Quantity-Limit Exception

    A request for a quantity above the program limit may be denied when the policy does not support the higher dose or the requested quantity exceeds the applicable FDA-labeled maximum without the required exception rationale.

    • Do not submit an above-limit quantity without higher-dose evidence or documentation explaining why a lower quantity of a higher strength cannot be used.
    • The requested quantity must remain within the maximum FDA-labeled dose when that maximum exists.

    Unsupported block type: denial_riskไcallout